Stability Biologics

Stability Biologics is a private, commercial-stage company operating in the regenerative medicine and advanced wound care sector. Its core business involves the development, manufacturing, and commercialization of a range of human tissue-based products, primarily derived from amniotic and other placental tissues, categorized as cellular, acellular, and matrix-like products (CAMPs). The company is actively generating evidence through a pivotal adaptive platform trial, STABLECAMP, focusing on hard-to-heal diabetic foot ulcers and venous leg ulcers, while also commercializing its products for various surgical and wound indications. With a focus on safety, science, and service, Stability Biologics aims to establish itself as a key provider of biologic solutions in a large and growing market.

Platform for processing human birth tissue (amniotic/placental) into a portfolio of cellular, acellular, and matrix-like products (CAMPs) for regenerative medicine applications.

Stability Biologics competes in the crowded human tissue-based product segment of the advanced wound care and surgical biologics market, against companies like Organogenesis (NuShield, PuraPly), MiMedx (EpiFix, AmnioFix), and Smith+Nephew (Santyl, Grafix), as well as numerous smaller private firms. Differentiation relies on product formulation, clinical evidence, and commercial execution.